- Dose range
- 0.25 → 2.0 mg/wk
- Route
- Subcutaneous injection, once weekly
- Indication(s)
- Type 2 diabetes; CV risk reduction in T2D + CVD
Titration schedule
| Step | Dose | Duration | Notes |
|---|---|---|---|
| 1 | 0.25 mg | Weeks 1-4 | Starter — does not provide glycemic control |
| 2 | 0.5 mg | Week 5 onward | Maintenance option |
| 3 | 1.0 mg | Increase after 4+ wks at 0.5 | Maintenance option |
| 4 | 2.0 mg | Maximum | Highest Ozempic T2D dose (added 2022) |
Important notes
- This FDA-approved drug dosing chart is intended as a reference for clinicians and patients reviewing protocols, not a substitute for individualized prescriber guidance.
- FDA-approved label dosing.
- Compounded versions, where applicable, must be prepared by a licensed 503A or 503B compounding pharmacy. FDA has warned compounders that used salt forms (semaglutide sodium and semaglutide acetate), which are not the active ingredient in any approved drug.
References
- Ozempic (brand semaglutide) prescribing information / clinical literature.
- FDA, bulk drug substances used in compounding under section 503A (interim categories), accessed October 2026.
- USP <797>: Pharmaceutical Compounding — Sterile Preparations.